MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

MAIA Biotechnology, Inc.AMEX: MAIA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $9.36M.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.34M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$9.36M+87.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Depreciation & Amortization vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 depreciation & amortization of $9.36M is the highest of the 7 companies compared; the peer median is $65.43K.
  • Its year-over-year change of +87.0% is the highest of 6, against a peer median of -49.1%.
MAIA Competitors Peer median
Depreciation & Amortization for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$9.36M +87.0%——
CELUCelularity Inc.LTM Dec 2025$7.34M -7.4%-8.2%27.6%
PYPDPolyPid Ltd.LTM Mar 2026$405.5K —-2.0%—
VERUVeru Inc.LTM Mar 2026$114.29K -49.1%-10.1%—
LTRNLantern Pharma Inc.LTM Mar 2026$16.56K -74.3%+19.7%—
RNXTRenovoRx, Inc.LTM Mar 2026$2K -99.9%-30.7%0.1%
ANVSAnnovis Bio, Inc.LTM Mar 2026$3 -25.0%——
Peer median (excluding MAIA) $65.43K-49.1%-8.2%13.9%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.45M8.93M11.11M10.01M14.55B
Selling, General & Admin4.29M6.14M9.07M6.95M9.72B
Operating Expenses7.79M16.18M20.18M16.96M24.27M
Depreciation & Amortization00000
EBITDA(11.75M)(15.76M)(19.77M)(23.25M)(22.4M)
EBITDA Margin—————
Operating Income(7.79M)(16.18M)(20.18M)(16.96M)(24.27M)
Operating Margin—————
Interest Income2.01K1.87K27.63K318.37K313.95K
Interest Expense827.54K6.97K0570
Other Income / Expenses(4.79M)406.92K409.48K(6.3M)1.87M
Income Before Tax(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.5M)(15.77M)(19.77M)(23.25M)(22.4M)
Net Margin—————
EPS (Basic)(1.18)(1.70)(1.49)(1.05)(0.70)
EPS (Diluted)(1.18)(1.70)(1.49)(1.05)(0.70)
Weighted Avg Shares10.64M9.28M13.26M22.2M32.12M
Weighted Avg Shares (Diluted)10.64M9.28M13.26M22.2M32.12M

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.